Posted 28th February 2018 by Jane Williams
7% of the population will be affected by a rare disease at some point in their lives. In anticipation of the Precision Medicine & Biomarkers Leaders Summit: USA and in recognition of Rare Disease Day, we have collated some of the top articles on rare diseases and their treatments.
Posted 21st February 2018 by Jane Williams
With just 3 months to go until the Precision Medicine & Biomarkers Leaders Summit: USA, we have taken some time to reflect on the Euopean Precision Medicine & Biomarkers Leaders Summit that took place in Munich in September.
Posted 14th February 2018 by Jane Williams
It was a pleasure to welcome back Miro Venturi to the Global Precision & Biomarkers Leaders Summit, our keynote speaker who spoke on the future of personalised medicine and the interplay of diseases, information and technologies. After his presentation, we sat down with him to get more of an insight into his thoughts on the future.
Posted 29th December 2017 by Jane Williams
Honey Reddi, Clinical Laboratory Director at the Jackson Laboratory spoke at the 4th Global Precision Medicine and Biomarkers Leader Summit. She gives us an insight on liquid biopsies in the clinic and the effectiveness of current treatment.
Posted 25th October 2017 by Jane Williams
Presented at the 4th Global Precision Medicine & Biomarkers Leader Summit, these slides are now available to download and share with your colleagues.
Posted 15th September 2017 by Jane Williams
In 2017, technological advances in cloud computing and artificial intelligence has pathology positioned to become one of the most talked about medical fields in healthcare.
Posted 11th September 2017 by Jane Williams
Non-invasive evaluation of molecular markers has shifted from the realm of prenatal diagnosis to tracking the effect of cancer treatment and management.
Posted 25th August 2017 by Jane Williams
Rheumatoid arthritis is one of the highest sources of the inefficiency of worldwide health care systems. This could be avoided by more tailored and individualised therapeutic strategies which require better molecular characterization of each patient.